You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. CATHEPSIN L INHIBITORS AS PAN CORONAVIRUS THERAPEUTICS

    SBC: PHELIX THERAPEUTICS LLC            Topic: R

    DESCRIPTION provided by applicant Coronaviruses CoV are RNA viruses that cause gastrointestinal respiratory and neurological symptoms in several mammalian species The outbreak of the severe acute respiratory syndrome CoV SARS CoV in humans was fatal in of infected patients infecting people and killing The recent incidents involving the highly pathogenic Middle East ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis This crisis has been further amplified by the recent emergence of the NDM andquot super bug geneandquot a zinc based metallo lactamase Amber Class B in Enterobacteriaceae Members of this family of resistance enzymes are found on promiscuous plasmids with other MDR resistance mechanisms ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    SBC: VenatoRx Pharmaceuticals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Multi drug resistance in Enterobacteriaceae is regarded as a healthcare crisis While carbapenems are among the most prescribed antibiotics for infections caused by these organisms carbapenem resistance conferred by zinc based metallo carbapenemases Amber Class B is a growing global health concern that threatens to erode the efficacy of these antibiotics both in th ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. CAD-CAM Technology for Diabetic Footwear

    SBC: DIAPEDIA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetes remains the leading cause of non-traumatic lower extremity amputations. Most amputations are preceded by a foot ulcer, so that successfully treating, or better still preventing, foot ulcers should reduce the n umber of diabetes related amputations. The majority of foot ulcers in diabetic patients are the result of loss of protective sensation (LOPS) s ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: R

    DESCRIPTION provided by applicant The smallpox virus variola has been responsible for the deaths of hundreds of millions of people worldwide Although smallpox was eradicated from the globe in following a valiant immunization campaign existing viral stocks may fall into the hands of those seeking to employ variola as a biological weapon This calls for the development of safe antiviral ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors

    SBC: KEYSTONE NANO, INC.            Topic: 102

    DESCRIPTIONprovided by applicantKeystone Nanoin partnership with the University of Maryland Greenebaum Cancer CenterUMD GCCproposes a multi site clinical evaluation of the Ceramide NanoLiposomeCNLas a novel anti cancer therapeuticThe overall objective of this project is to advance the CNL through a Phase I clinical trialThe results of this trial will support subsequent trials for the intended init ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Remote Brief Intervention and Referral to Treatment Service for Alcohol (R-BIRT)

    SBC: POLARIS HEALTH DIRECTIONS, INC            Topic: NIAAA

    DESCRIPTIONprovided by applicantSignificanceThe USPHSTFSAMHSACDCand NIAAA have affirmed the importance of screening in medical settings for alcohol consumption that exceeds the NIAAA low risk limitsbrief educational and motivational counseling for those who screen positive or have other evidence of an Alcohol Use Disorderandwhen appropriatereferral to treatmentSBIRTHowevertranslation to clinical p ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Clinical Trial of ABC in Patients with Refractory Multiple Myeloma

    SBC: Apogee Biotechnology Corporation            Topic: NCI

    DESCRIPTION provided by applicant Multiple myeloma MM is the second most common hematological malignancy in the United States and remains an incurable disease since nearly all MM patients will eventually relapse and develop resistance to currently available drugs Sphingolipid metabolism is being increasingly recognized as a key pathway in tumor biology In particular sphingosine kinases S ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)

    SBC: IMCARE BIOTECH            Topic: NCI

    DESCRIPTIONprovided by applicantHepatocellular carcinomaHCCis usually undetected until its later stageswhere theyear survival rate for patients is less thanHoweverthe survival rate can be as high asif the cancer is detected earlyUnfortunatelyearly detection of HCC is not possible with any screening tests that are currently availablesuch as ultrasound or imaging technologiesAlpha FetoproteinAFPwhic ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of metastatic melanoma acting via a novel glutamatergic mechanism of action, and also be useful to treat amyotrophic lateral sclerosis (ALS) and the many other conditions for which riluzole itself is un ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government